Publication: Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Bernatsky, S., H. A. Velásquez García, J. J. Spinelli, P. Gaffney, K. E. Smedby, R. Ramsey-Goldman, S. S. Wang, et al. 2017. “Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma.” Lupus Science & Medicine 4 (1): e000187. doi:10.1136/lupus-2016-000187. http://dx.doi.org/10.1136/lupus-2016-000187.
Research Data
Abstract
Objective: Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genome-wide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL. Methods: GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis. Results: Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765. Conclusions: These data suggest several plausible genetic links between DLBCL and SLE.
Description
Other Available Sources
Keywords
lymphoma, Systemic lupus, malignancy
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service